228 related articles for article (PubMed ID: 26028645)
21. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
22. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
Devarakonda S; Rotolo F; Tsao MS; Lanc I; Brambilla E; Masood A; Olaussen KA; Fulton R; Sakashita S; McLeer-Florin A; Ding K; Le Teuff G; Shepherd FA; Pignon JP; Graziano SL; Kratzke R; Soria JC; Seymour L; Govindan R; Michiels S
J Clin Oncol; 2018 Oct; 36(30):2995-3006. PubMed ID: 30106638
[TBL] [Abstract][Full Text] [Related]
23. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
24. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
26. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Reiman T; Lai R; Veillard AS; Paris E; Soria JC; Rosell R; Taron M; Graziano S; Kratzke R; Seymour L; Shepherd FA; Pignon JP; Sève P
Ann Oncol; 2012 Jan; 23(1):86-93. PubMed ID: 21471564
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy after pulmonary resection for lung cancer.
Mascaux C; Shepherd FA
Thorac Surg Clin; 2013 Aug; 23(3):401-10. PubMed ID: 23931022
[TBL] [Abstract][Full Text] [Related]
28. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
Han Y; Wang XB; Xiao N; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
[TBL] [Abstract][Full Text] [Related]
29. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
[TBL] [Abstract][Full Text] [Related]
30. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
Interact Cardiovasc Thorac Surg; 2013 Feb; 16(2):166-72. PubMed ID: 23143203
[TBL] [Abstract][Full Text] [Related]
31. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
32. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
33. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
Cui Y; Wang W; Yao S; Qiu Z; Cong L
J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
[TBL] [Abstract][Full Text] [Related]
34. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.
Cuffe S; Booth CM; Peng Y; Darling GE; Li G; Kong W; Mackillop WJ; Shepherd FA
J Clin Oncol; 2012 May; 30(15):1813-21. PubMed ID: 22529258
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni L; Vavalà T; Novello S
Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
[TBL] [Abstract][Full Text] [Related]
38. Personalized therapy for non-small cell lung cancer: which drug for which patient?
Villaruz LC; Socinski MA
Semin Thorac Cardiovasc Surg; 2011; 23(4):281-90. PubMed ID: 22443647
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
Choong NW; Vokes EE
Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S98-104. PubMed ID: 16384544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
